Joanna Baginska, Allison Nau, Ilana Gomez Diaz, Anita Giobbie-Hurder, Jason Weirather, Juliana Vergara, Charlotte Abrecht, Margaret Hallisey, Jenna Dennis, Mariano Severgnini, Julia Huezo, Isabella Marciello, Osama Rahma, Michael Manos, Andrew S Brohl, Philippe L Bedard, Daniel J Renouf, Elad Sharon, Howard Streicher, Patrick A Ott, Elizabeth I Buchbinder, F Stephen Hodi
BACKGROUND: Vascular endothelial growth factor is associated with reduced immune response and impaired anti-tumor activity. Combining antiangiogenic agents with immune checkpoint inhibition can overcome this immune suppression and enhance treatment efficacy. METHODS: This study investigated the combination of ziv-aflibercept anti-angiogenic therapy with pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. Baseline and on-treatment plasma and PBMC samples were analyzed by multiplex protein assay and mass cytometry, respectively...
January 18, 2024: Cancer Immunology, Immunotherapy: CII